0
Clinical Investigations: ASTHMA |

A Controlled Trial of Chlorofluorocarbon-Free Triamcinolone Acetonide Inhalation Aerosol in the Treatment of Adult Patients With Persistent Asthma*

Michael Welch, MD; David Bernstein, MD; Gary Gross, MD; Robert E. Kane, MS; Donald Banerji, MD; the Azmacort HFA Study Group
Author and Funding Information

Affiliations: *From the Allergy & Asthma Medical Group & Research Center (Dr. Welch), San Diego, CA; Bernstein Clinical Research Center (Dr. Bernstein), Cincinnati, OH; Pharmaceutical Research & Consulting, Inc. (Dr. Gross), Dallas, TX; and Rhône-Poulenc Rorer (Mr. Kane and Dr. Banerji), Collegeville, PA. ,  A complete list of participants is located in the Appendix.

Correspondence to: Michael Welch, MD, Allergy & Asthma Medical Group & Research Center, 9610 Granite Ridge Dr, Suite B, San Diego, CA 92123; e-mail: mwelch@pol.net


Affiliations: *From the Allergy & Asthma Medical Group & Research Center (Dr. Welch), San Diego, CA; Bernstein Clinical Research Center (Dr. Bernstein), Cincinnati, OH; Pharmaceutical Research & Consulting, Inc. (Dr. Gross), Dallas, TX; and Rhône-Poulenc Rorer (Mr. Kane and Dr. Banerji), Collegeville, PA. ,  A complete list of participants is located in the Appendix.


Chest. 1999;116(5):1304-1312. doi:10.1378/chest.116.5.1304
Text Size: A A A
Published online

Study objective: To compare the dose response, efficacy, and safety of inhaled triamcinolone acetonide (TAA) with a hydrofluoroalkane (HFA) propellant (75 μg/puff), TAA with a chlorofluorocarbon propellant (dichlorodifluoromethane [P-12]; 75μ g/puff), and placebo in adult patients with persistent asthma.

Design: Multicenter, randomized, double-blind, placebo-controlled, parallel-group study of 514 adult patients with persistent asthma.

Interventions and measurements: Patients received 8 weeks of treatment with 150, 300, or 600 μg/d of TAA HFA, the same doses of TAA P-12, or placebo following a 5- to 21-day baseline period. Efficacy was assessed by spirometry, and by daily recordings of albuterol use, peak expiratory flow (PEF), asthma symptom ratings, and nighttime awakenings throughout the study.

Results: Linear trend analysis showed that both formulations of TAA at all doses produced statistically significant improvements compared with placebo in spirometry, asthma symptom scores, albuterol use, and PEF. Significant improvement was seen as early as 24 h for morning PEF and as early as 1 week for FEV1 (TAA HFA, 600 μg/d; TAA P-12, 300 and 600 μg/d) and albuterol use (all doses of both formulations). The P-12 and HFA formulations had comparable efficacy. A dose response showing greater improvement with higher doses was evident for the majority of parameters for both formulations. The incidences of adverse events were similar across all treatment groups with no dose-related trends.

Conclusion: HFA and P-12 formulations of TAA inhalation aerosol were therapeutically equivalent and showed comparable safety and dose-related efficacy in the treatment of patients with persistent asthma.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
Asthma in pregnancy.
American College of Obstetricians and Gynecologists | 9/19/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543